An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP‐induced hyperaggregabiIity in streptozotocin‐induced diabetic rats

Authors:

Abstract
Rats with streptozotocin‐induced diabetes were oral given TAT, a potent aldose reductase inhibitor, at a dose of 10 rng kg‐1 day‐1or 40 mg kg‐1 day‐1 for 30 days. Prolongation of the peak latency of oscillatory potentials in the b‐wave of the electro‐retinogram (ERG), which is associated with retinal Müller cell dysfunction, was significantly improved by treatment with TAT as compared with untreated diabetic rats [Σ(O1+O2+ O3) was 106.8 ± 1.8 ms in normal controls (NC), 118.2 ±1. 1 ms in diabetic controls (DC) (P ‐1TAT (P< 0.001 vs. DC) and 111.4 ±1.6ms with 40 mg kg‐1 TAT (P<0.01 vs. DC)]. The improvement in ERG abnormalities in diabetic rats was accompanied by partial reduction of elevated sorbitol levels in the retina and erythro‐cytes, and by correction of platelet hyperaggregability. The authors' findings suggest that a better understanding of the mechanism by which TAT acts may provide new insights into the pathogenesis of hyper‐glycaemic retinal dysfunction and contribute to establishing effective therapy for diabetic retinopathy.

This publication has 40 references indexed in Scilit: